secwatch.observer — SEC 8-K summary
======================================

Issuer:     Arcus Biosciences, Inc. (RCUS)
CIK:        0001724521
Form:       8-K
Filed at:   2026-10-21T20:09:43+00:00
Accession:  0001193125-26-427829
Event type: other_material
Sentiment:  neutral
Materiality: 0.40
Item codes: 2.02
LLM model:  deepseek-v4.1-flash:cloud@v2

Arcus Biosciences pegs Sept 30, 2026 cash and marketable securities at ~$694.0M
-------------------------------------------------------------------------------

- Preliminary estimate of approximately $694.0 million in cash, cash equivalents and marketable securities as of September 30, 2026.
- Filing discloses no revenue, EPS, burn rate or cash runway figures; it is a cash-balance update only.
- Estimate is unaudited and subject to completion of financial closing procedures; Ernst & Young has not audited, reviewed or compiled the figure.
- Company cautions the balance may vary from the actual September 30, 2026 position and is not indicative of future periods.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1724521/000119312526427829/0001193125-26-427829-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1724521/000119312526427829/d130368d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-26-427829

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer